Junshi Biosciences Doses First Patient in Phase III Trial of JS203 Plus Chemotherapy for Lymphoma

• Shanghai Junshi Biosciences announced first-patient dosing in its first registrational Phase III trial of JS203 on October 23, 2026.
• The trial compares JS203 plus chemotherapy with rituximab plus chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
• Planned enrollment is 282 patients, with overall survival as the primary endpoint.
• Phase I results were previously presented at the AACR meeting in April 2025, with updated findings at ASH in December 2025.
• Those findings showed promising antitumor activity, durable responses and a manageable safety profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12382100), on October 23, 2026, and is solely responsible for the information contained therein.